Improving quality control for CAR T cell therapies
Drug Discovery World
AUGUST 10, 2022
In 1987, researchers developed the chimeric antigen receptor (CAR) as an alternative means to identify cancer cells and direct T cells to attack them. Exactly three decades later, the first CAR T cell therapy hit the market. Training T cells to target tumours.
246 
Let's personalize your content